



## CORPORATE INFORMATION

### Pulmo BioTech Incorporated

Registered Address:  
1035 Park Avenue, Suite 7B  
New York, NY 10028-0912  
Tel: +1 (646) 827 9362  
Fax: +1 (646) 827 9362  
Website: [www.pulmobiotech.com](http://www.pulmobiotech.com)

State of Incorporation: Delaware  
Date of fiscal year end: 03/31  
IS IN: US7458451 074  
CUSIP: 745845107  
WKN: A0RDTZ

## SEC CORPORATE LEGAL COUNSEL

### Hirshfield Law

Peter Hirshfield  
1035 Park Avenue  
Suite 7B  
New York, NY 10028-0912  
USA

## AUDITORS

### Raich Ende Malter & Co. LLP Certified Public Accountants

1375 Broadway  
New York, New York 10018  
USA

## TRANSFER AGENT

### Interwest Transfer Company, Inc.

1981 Murray Holladay Road, Suite 100  
Salt Lake City, UT 84117  
USA

## INVESTOR RELATIONS

Garry McCann CEO  
[garry.mccann@pulmobiotech.com](mailto:garry.mccann@pulmobiotech.com)

## ABOUT THE COMPANY

Pulmo BioTech Inc is a public company bringing innovative and exciting medical diagnostic technologies to the marketplace. The company's shares are dual listed on the OTC:BB in the US under the symbol PLMO.OB and on the Open market in Frankfurt under the symbol PBO.F

The addressable annual market for its product candidates is estimated to be in excess of \$1 billion.

## WHAT IS THE PRODUCT AND WHY IS THIS INTERESTING?

- PulmoBind is a patented radio-tracer marked peptide which will bond to the inner vascular wall of the Pulmonary Circulatory system after it has been administered intravenously
- Because the radio-tracer is a gamma emitter, the position and density of the PulmoBind molecules can be "seen" by a gamma camera (a piece of equipment available in every hospital's Nuclear Medicine department)
- This will allow the 3D visualisation of Pulmonary Embolisms as well as the diagnosis of Pulmonary Hypertension and Chronic Obstructive Pulmonary Disorder
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disorder (COPD) and other medical problems afflicting the Pulmonary Circulation remain an area where there is no simple front-line diagnostic test – Orphan Conditions
- 200,000 people in the US alone die from Pulmonary Embolism each year
- Pulmonary Hypertension is frequently misdiagnosed or not diagnosed at all – early diagnosis might improve the survival rate dramatically
- There is currently no simple front-line diagnostic test for Pulmonary Hypertension
- PulmoBind can be used by any hospital that has a Nuclear Medicine Department (the majority of hospital worldwide plus a very large number of clinics)
- There will be no need for the hospitals to buy any extra capital equipment. Their existing Gamma Cameras will be all that is required
- There will be no need for hospitals to change any of their operational procedures to use PulmoBind
- The radio-marker used by PulmoBind is Tc99m – the most common medical radio-isotope in the world and available in every hospital with a Nuclear Medicine Department

## MARKET PROSPECTS FOR PULMOBIND

- Main Market Areas are the Diagnosis of:
  - Pulmonary Embolism
  - Pulmonary Hypertension
  - Chronic Obstructive Pulmonary Disorder (COPD)
  - Lung Inflammatory Conditions
- Pulmonary Embolism Market is estimated to be worth \$600 million per annum globally
- The markets for the other conditions that PulmoBind can diagnose do not exist as yet – how large could they become?
- PulmoBind has the potential to become a routine Front Line Diagnostic test
- Every time somebody tells their Doctor they have shortness of breath – prescribe a PulmoBind scan?
- Imagine the market if PulmoBind became as common a diagnostic tool as a chest x-ray
- So how big is the potential market for PulmoBind?
  - Larger than \$600 million per annum
  - How much larger?
  - \$1 billion? \$2 billion? More?

## WHO ARE THE PEOPLE BEHIND THIS

Garry McCann, Director & CEO

Garry, age 50, is also the Managing Director of MC&C td, a UK business consulting company. Prior to these positions he was the Managing Director of NE Technology Ltd, a global leader in the design and manufacture of radiation detection equipment. Garry has also been active in the fields of CAT X-ray generators, medical imaging CCDs, IR Image Sensors and medical Linear Accelerator systems. Garry has an MBA from Warwick University Business School and a BSc (Hons) in Physics from the University of Surrey.

Professor John Wallwork, Chairman

John is currently Professor of Cardiothoracic Surgery and Director of Research & Development at Papworth Hospital NHS Foundation Trust, Cambridge. He performed Europe's first successful heart-lung transplant in 1984 and, with Professor Sir Roy Calne, the world's first heart-lung and liver transplant in 1986. During this period he and his colleague, Professor Tim Higenbottam, were the first to introduce the use of long-term Prostacycline for Primary Pulmonary Hypertension.

Doctor Jocelyn Dupuis, Chief Scientific Officer

Jocelyn is the lead researcher for the company as well as being the originator of the technology that underlies Pulmo BioTech's molecular imaging products. He has over 15 years of research experience in pulmonary physiology and is a Cardiologist and Physiologist. He has had 75 papers published, has given 55 presentations at conferences as a guest speaker and has 96 abstracts published.

Rajiv Garg, Chief Financial Officer

Rajiv has twenty-one years of extensive experience in the investment banking and finance industry covering financial control, evaluation of businesses, regulatory liaison and development of macro/micro risk management systems. Rajiv was educated at Westminster College in London, UK and the University of Delhi in India. He has an Honors Degree in Commerce and is a Member of the Institute of Chartered Accountants, a Member of the Securities and Futures Authority and a Member of the Global Association of Risk Professionals.

Ian Isley, Director

Ian, age 58, since 1984 has been the Managing Director of Bureau d'Administration de Services et d'Etudes (Monaco), a small but long-established Monegasque financial services and management consulting business that offers trust, offshore management and tax planning and related activities. Mr. Isley holds a degree in accountancy and business studies from Thames Valley University and is qualified as a Chartered Certified Accountant.

## WHAT STAGE IS THE COMPANY AT NOW

- Pulmo BioTech Inc is an early stage development company.

- The company is currently completing Regulatory Approval experiments as a precursor to starting Phase I Human Trials of its PulmoBind product candidate.
- Phase I Trials are expected to be completed during 2010

## WHAT ARE THE COMPANY'S PLANS

- Following successful completion of the Phase I Human Trials, the company plans to start Phase II/III Trials for the diagnosis of Pulmonary Hypertension. Since this is an "orphan condition" the Trials are expected to be completed in an 18 month time frame which will then lead to immediate product sales.
- On completion of the Phase II/III work and with the start of PH diagnostic sales, the company will then seek to carry out trials of PulmoBind against Pulmonary Embolism (PE), Chronic Obstructive Pulmonary Disorder (COPD) and other conditions affecting the pulmonary vascular system. This will open up to the company a market worth in excess of \$1 billion per annum.
- First year sales following the launch of a PH specific diagnostic are estimated to be \$30million rising to \$82million in year 2

## INVESTMENT HIGHLIGHTS

- Product has anticipated healthy gross margins of 70%
- Patent protected
- Huge target market size
- Virtually debt-free (Only a Loan Note to related party)
- Major technology risks already absorbed